drugset
drugset / Trial / NCT03282435

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

NCT03282435 ↗

Phase 1 Unknown 30 enrolled Dalian University
RandomizedFactorialQuadruple-blindTreatment

Summary

to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy

Timeline

Start
2018-01
Primary completion
2023-01
Completion
2023-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator CIK cells Cell therapy — —

Indications

non-small cell lung carcinoma